Dr. Joseph Raffaele on the Role of Biomarkers in Longevity Medicine
Dr. Joseph Raffaele, CEO of PhysioAge Health Analytics, emphasizes that measuring aging is fundamental to treating it effectively. According to him, biomarkers are essential for providing a feedback loop that helps physicians track the effectiveness of their interventions over time. Without these measurable metrics, the practice of longevity medicine becomes a matter of guesswork rather than a science-driven approach.
The Importance of a Multi-Omics and N-of-1 Approach
Raffaele advocates for a multi-omics approach to capture the complexity of the aging process. He points out that different biological „clocks“ (such as epigenetic and functional biomarkers) measure different aspects of aging and may not always align. A patient’s aging profile is often a „mosaic of strengths and weaknesses,“ where one organ system may be aging faster than another. To get a complete and useful picture, physicians need to measure a wide range of biomarkers across multiple organ systems.
This leads to the concept of „n-of-1“ precision longevity medicine, where each patient is treated as a unique case. Raffaele stresses that personalized interventions should be based on a broad integration of data from an individual’s biology, rather than a one-size-fits-all approach. For example, he has been tracking telomere length in patients since 2007. He notes that longitudinal data—tracking changes over years—is more valuable than a single measurement. He has observed instances where a patient’s telomere length remained stable for a decade, only to show a sudden drop after a major event like a COVID-19 infection, highlighting how dynamic the aging process is.
The upcoming Global Longevity Summit in Geneva, themed „Mastering the Aging Clock,“ will feature Dr. Raffaele alongside other experts like Dr. Steve Horvath, to discuss how these concepts are being applied in clinical practice to create safe, effective, and personalized longevity medicine.